An independent data monitoring committee (IDMC) has recommended the continuation of Argos’ pivotal phase 3 ADAPT clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC) based on results of the committee’s second planned interim data analysis. The next planned interim analysis will be in 6 months. Continue reading
Tag Archives: CSF-1
CSF-1 Inhibitor PLX3397 + Keytruda (Anti-PD1) for Multiple Cancers
Colony Stimulating Factor (CSF-1) is an essential growth factor for cells of the monocyte-macrophage lineage, including osteoclasts.